17,261 trials
Influenza
Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711
Allergy · Immune Tolerance · Injection Site Discomfort
Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale
Carcinomatous Edema
Primary: Change in Body Weight From Baseline at Final IMP Administration — -0.69; -0.34; -1.13; 0.70 Kg
Alcoholism
Primary: Startle Potentiation During Stress Reactivity Task — 22.25; 20.76; 26.22; 22.21 microvolts
Cancer-related Cognitive Difficulties
Primary: Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm — 75.2; 82.7; 83.6; 74.3 % correct — p=0.9168
Acute Myeloid Leukemia
Primary: Proportion of Participants With Relapse Free Survival (RFS) up to 18 Months Post Transplant (Full Analysis Set) by Kaplan-Meier Analysis — 0.93; 0.93; 0.80; 0.93…
Cancer · Melanoma
Primary: Objective Response Rate (ORR) — 61 Percentage of Participants
Retinal Vein Occlusion
Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…
Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant
Primary: Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability] — 9; 15; 12; 0 Participants
Visual Acuity
Primary: Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population) — -0.111; -0.109; -0.115; -0.118 logMAR
Small Cell Lung Cancer · Small Cell Lung Cancer Extensive Stage
Primary: Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate — 7.4 GBq
Multiple Myeloma
Primary: Mean Multiple Myeloma Lesions Detected — 4.6; 4.4; 1.1; 1.0 number of lesions
Dyslipidemia
Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001
Cardiovascular Diseases · Cardiovascular Abnormalities · Calcifications, Vascular
Primary: Change in Log CAC Volume Score From Baseline to Week 52 for the Combined Dose Groups vs Placebo — 1.11; 1.20 ratio
Palmar Hyperhidrosis
Primary: Mean Change From Baseline to Week 2 in Hand Sweating Severity Score — -2.14; -0.56; -1.64; -3.03 score on a scale — p=0.244